<DOC>
	<DOCNO>NCT02197767</DOCNO>
	<brief_summary>Will use Rituximab reduce proteinuria 12 month period preservation kidney function use study drug ?</brief_summary>
	<brief_title>Pilot Study Rituximab Treat Fibrillary Glomerulonephritis</brief_title>
	<detailed_description>This Phase II , open-label study determine use Rituximab reduce proteinuria 12 month period preservation kidney function use study drug . Aim 1 ) Preservation kidney function 12 month define stable improve 24 hour creatinine clearance . Aim 2 ) Reduction proteinuria 12 month &amp; improve quality life 12 month validate questionnaire .</detailed_description>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Fibrillary Glomerulonephritis diagnostic biopsy perform within last 2 year Proteinuria &gt; 1 gram Age &gt; 18 year &lt; 80 year Adequately control blood pressure ( BP &lt; 140/90 mmHg &gt; 75 % reading ) least 3 month prior enrollment use ACEi and/or ARB , tolerate . Women must post menopausal , surgically sterile practice medically approve method contraception Able willing give write informed consent comply requirement study protocol Adequate renal function indicate estimate GFR &gt; 25 mL/min use CKD/EPI formula quantify creatinine clearance &gt; 25 mL/min , and/or serum creatinine &lt; 3.0 mg/dL presence ACEi/ARB therapy Adequate bone marrow function , indicate hemoglobin &gt; 7.0 gm/dL , white count &gt; 3.0 x 10 ( 9 ) , platelet count &gt; 100 x 10 ( 9 ) Negative chest xray within one year Negative serum pregnancy test ( woman child bear age ) Normal organ function . Subject agree use acceptable method birth control treatment twelve month completion treatment Subject provide write informed consent Subject agree discontinue routine use nonsteroidal antiinflammatory drug ANC : &gt; 1000/ mm3 ( Absolute Neutrophil Count ) Adequate liver function , indicate AST , ALT , alkaline phosphatase total bilirubin &lt; 2x upper limit normal unless related primary disease Negative HBsAg antiHBc lab value within 1 year signing consent Pregnancy ( determine serum pregnancy test woman childbearing potential within 7 day treatment ) , lactate . Inability comply study and/or followup procedure History HIV ( document positive lab value within one year enrollment ) Presence active infection New York Heart Association Classification III IV heart disease Concomitant malignancies previous malignancy within last five year , exception adequately treat basal squamous cell carcinoma skin carcinoma situ cervix History psychiatric disorder At Investigator 's discretion , receipt live vaccine within 4 week prior randomization At Investigator 's discretion , positive Hepatitis C serology Known history diabetes mellitus Hemoglobin A1c result &gt; 6.0 % within 90 day prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>fibrillary GN</keyword>
	<keyword>rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>MabThera</keyword>
	<keyword>Zytux</keyword>
</DOC>